Luteolin and its inhibitory effect on tumor growth in systemic malignancies.
Exp Cell Res
; 319(6): 777-8, 2013 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-23333558
ABSTRACT
Lamy et al have provided interesting data in their recent article in your esteemed journal. Luteolin augments apoptosis in a number of systemic malignancies. Luteolin reduces tumor growth in breast carcinomas. Luteolin mediates this effect by up-regulating the expression of Bax and down-regulating the expression of Bcl-xL. EGFR-induced MAPK activation is also attenuated. As a result there is increased G2/ M phase arrest. These effects have been seen both in vivo as well as in vitro. It also reduces ERα expression and causes inhibition of IGF-1 mediated PI3K-Akt pathway. Luteolin also activates p38 resulting in nuclear translocation of the apoptosis-inducing factor. Simultaneously it also activates ERK. As a result there is increased intra-tumoral apoptosis which is caspase dependent as well as caspase independent.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Interleucina-6
/
Inibidores da Angiogênese
/
Fator de Transcrição STAT3
/
Polifenóis
Limite:
Humans
Idioma:
En
Revista:
Exp Cell Res
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos